Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study

Firatli

et al. 2022

CIMB

This study aimed to compare tissue levels of CD80 (pro-inflammatory macrophage-related surface marker), CD163, and CD206 (anti-inflammatory macrophage-related surface markers), and their ratios in periodontal and peri-implant health and disease. Altogether, 36 tissue samples were obtained from 36 participants with clinically healthy gingiva (n = 10), healthy peri-implant mucosa (n = 8), periodontitis lesions (n = 9), and peri-implantitis lesions (n = 9). CD80, CD163, and CD206 levels were assessed with immunoblotting. CD163 levels were found to be decreased (p = 0.004), and the CD80/CD163 ratio was found to be elevated (p = 0.002) in periodontitis lesions compared to healthy gingiva. Peri-implantitis lesions showed a tendency towards a higher CD80/CD163 ratio than in healthy peri-implant mucosa with a borderline difference (p = 0.054). No statistically significant difference was detected in CD80, CD163, and CD206 levels of periodontitis lesions when compared to peri-implantitis, and in healthy gingiva when compared to healthy peri-implant mucosa. A disruption in CD80/CD163 balance seems to be related to the pathogenesis of periodontitis and peri-implantitis, being less prominent in the latter. The reason behind this phenomenon may be either suppressed CD163 expression or reduced CD163+ anti-inflammatory macrophage abundance.

Section: Discussionmentioning

confidence: 99%

Tissue Levels of CD80, CD163 and CD206 and Their Ratios in Periodontal and Peri-Implant Health and Disease

Firatli

et al. 2022

CIMB

“…Eligible individuals who have less than 15 teeth, have any systemic disease with potential impact to the inflammatory status or periodontal condition, smoke occasionally (<5 cigarettes/day) or are former smokers, taken any antimicrobial or anti‐inflammatory medicine in the previous 3 months, use contraceptives or are pregnant or in lactation were excluded. The periodontitis group of the current study was formed from the same individuals as in our previous publication, while the control group was primarily composed of different individuals 14 …”

Section: Methodsmentioning

confidence: 99%

“…This study was conducted as a continuation of the project, which was registered on clini caltr ials.gov with the number NCT04792372. 14 The study's accordance with the ethical principles of the Helsinki declaration was approved by the Ethics Committee of Biruni University's Medical Faculty, Türkiye (2015-KAEK- 43-19-27). All participants were informed about the study protocol and signed written informed consent.…”

Section: Participant Recruitmentmentioning

confidence: 99%

“…The estimation was based on the difference between two independent means of gingival crevicular fluid TWEAK levels in periodontitis and those in periodontal health as reported before. 14,24 A minimum required sample size of 48 participants in total (smoker periodontitis vs. periodontally healthy and nonsmoker periodontitis vs. periodontally healthy) was calculated (α = 0.05; 1 − β = 0.95; lymphocytes, macrophages, periodontitis, saliva periodontitis and periodontally healthy subjects with at most 10% full-mouth bleeding on probing score and no sites with pocket depth >3 mm as controls were included in the study. 25 The grade was assigned based on indirect evidence of disease progression (percent bone loss/age) and the impact of smoking.…”

Section: Participant Recruitmentmentioning

confidence: 99%

“…The CD163/TWEAK ratio has been associated with inflammatory conditions such as skin lesions and cardiovascular events 13 . Recently, our group revealed that baseline tissue levels of CD163 and the CD163/TWEAK ratio are associated with pocket healing following nonsurgical treatment 14 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Salivary levels of BAFF, TWEAK, and soluble CD163 and salivary arginase activity before and after periodontal treatment

J of Periodontal Research

Gürsoy

et al. 2023

Self Cite

Objective: To monitor salivary B-cell activating factor (BAFF), tumor necrosis factorlike weak inducer of apoptosis (TWEAK), and soluble (s)CD163 levels and arginase activity in periodontitis patients following nonsurgical periodontal treatment.Background: BAFF, TWEAK, and sCD163 and arginase are associated with activities of B cells and macrophages, which are important regulators of periodontal immuneinflammatory response and healing following treatment. Increased salivary BAFF and sCD163 levels and arginase activity in periodontitis have been demonstrated, but their changes following treatment have not been evaluated before.Materials and Methods: Forty-four Stage III/IV periodontitis patients and 35 periodontally healthy controls were included in the study. Full-mouth periodontal measurements were recorded and unstimulated saliva was obtained from all participants at baseline. Sample collection and measurements were repeated in periodontitis patients at 2, 6, 12, and 24 weeks following full-mouth scaling and root debridement, whereas controls were only seen at baseline. BAFF, TWEAK, and sCD163 levels were analyzed with bead-based multiplexed immunoassay. Arginase activity was measured with Chinard's method.Results: BAFF (p < .001) and sCD163 (p = .003) levels and arginase activity (p < .015) were higher in periodontitis patients compared to healthy controls. BAFF levels (p < .001) and arginase activity (p < .001) of periodontitis patients were reduced at 2 weeks posttreatment and continued to decrease up to 6 (p = .038) and 12 weeks (p = .024), respectively. The reduction of sCD163 levels became significant (p = .003) at 24 weeks posttreatment. Conclusions:The decrease in salivary BAFF levels 2 weeks after periodontal treatment indicates a change in cell signaling toward limited B-cell activation. Decreasing arginase activity similarly reflects a significant reduction in inflammatory response.The reduction in sCD163 levels that are observed at 24 weeks may reflect a longstanding anti-inflammatory macrophage activation, given their multiple functions in immune response, inflammation, and healing.

Baseline interleukin‐10, CD163, and tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) gingival tissue levels in relation to clinical periodontal treatment outcomes: A 12‐week follow‐up study

Journal of Periodontology

Gürsoy

et al. 2022

Background:The aim of this study was to examine the relationship between healing response after non-surgical periodontal treatment and baseline gingival tissue levels of M2 macrophage activation-related proteins CD163, interleukin (IL)-10, interferon (IFN)-γ, and tumor necrosis factor-like weak inducer of apoptosis (TWEAK), and the CD163/TWEAK ratio. Methods: Eighty-eight gingival tissue samples from 44 Stage III/IV, Grade C periodontitis patients (18 smokers) and 41 tissue samples from 41 periodontally healthy participants (18 smokers) were evaluated. Clinical parameters were recorded in periodontally healthy individuals at baseline and in periodontitis patients at pre-treatment and 2, 6, and 12 weeks following therapy. IL-10, IFN-γ, CD163, and TWEAK levels were analyzed with Luminex technique.Results: Tissue levels (median, 1 st -3 rd quartile) of IL-10 (pg/ng protein), CD163 (pg/μg protein) and TWEAK (pg/μg protein) were as follows: IL-10 periodontitis: